BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24634115)

  • 1. Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing.
    Huang Y; Zheng J; Hu JD; Wu YA; Zheng XY; Liu TB; Chen FL
    Genet Mol Res; 2014 Feb; 13(1):945-53. PubMed ID: 24634115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model.
    Kazemi-Sefat GE; Keramatipour M; Vaezi M; Razavi SM; Kavousi K; Talebi A; Rostami S; Yaghmaie M; Chahardouli B; Talebi S; Mousavizadeh K
    Sci Rep; 2022 Jul; 12(1):12816. PubMed ID: 35896598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia.
    Mori N; Morosetti R; Spira S; Lee S; Ben-Yehuda D; Schiller G; Landolfi R; Mizoguchi H; Koeffler HP
    Blood; 1998 Nov; 92(9):3405-9. PubMed ID: 9787180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
    Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S
    Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CML: mechanisms of disease initiation and progression.
    Wetzler M; Talpaz M; Estrov Z; Kurzrock R
    Leuk Lymphoma; 1993; 11 Suppl 1():47-50. PubMed ID: 8251916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
    Gaiger A; Henn T; Hörth E; Geissler K; Mitterbauer G; Maier-Dobersberger T; Greinix H; Mannhalter C; Haas OA; Lechner K; Lion T
    Blood; 1995 Sep; 86(6):2371-8. PubMed ID: 7662984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.
    Ko TK; Javed A; Lee KL; Pathiraja TN; Liu X; Malik S; Soh SX; Heng XT; Takahashi N; Tan JHJ; Bhatia R; Khng AJ; Chng WJ; Sia YY; Fruman DA; Ng KP; Chan ZE; Xie KJ; Hoi Q; Chan CX; Teo ASM; Velazquez Camacho O; Meah WY; Khor CC; Ong CTJ; Soon WJW; Tan P; Ng PC; Chuah C; Hillmer AM; Ong ST
    Blood; 2020 Jun; 135(26):2337-2353. PubMed ID: 32157296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High frequency of RAS oncogene mutation in chronic myeloid leukemia patients with myeloblastoma.
    Tanaka K; Takauchi K; Takechi M; Kyo T; Dohy H; Kamada N
    Leuk Lymphoma; 1994 Apr; 13(3-4):317-22. PubMed ID: 8049652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
    Rooke HM; Vitas MR; Crosier PS; Crosier KE
    Leukemia; 1999 Apr; 13(4):535-41. PubMed ID: 10214859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology.
    Dazzi F; Capelli D; Hasserjian R; Cotter F; Corbo M; Poletti A; Chinswangwatanakul W; Goldman JM; Gordon MY
    Blood; 1998 Aug; 92(4):1390-6. PubMed ID: 9694728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosomal characteristics of Ph-positive chronic myelogenous leukemia in transformation. A study of 23 Chinese patients in Taiwan.
    Tien HF; Chuang SM; Wang CH; Lee FY; Chien SH; Chen YC; Shen MC; Liu CH
    Cancer Genet Cytogenet; 1989 May; 39(1):89-97. PubMed ID: 2731152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia.
    Zhang SJ; Ma LY; Huang QH; Li G; Gu BW; Gao XD; Shi JY; Wang YY; Gao L; Cai X; Ren RB; Zhu J; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2076-81. PubMed ID: 18250304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research on epigenetic mechanism of SFRP2 in advanced chronic myeloid leukemia.
    Li Z; Luo J
    Biochem Biophys Res Commun; 2018 Jun; 501(1):64-72. PubMed ID: 29704505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of secondary chromosomal aberrations of chronic myelocytic leukemia.
    Wang Y; Hopwood VL; Hu P; Lennon A; Osterberger J; Glassman A
    Cancer Genet Cytogenet; 2004 Aug; 153(1):53-6. PubMed ID: 15325094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism.
    Zhang SJ; Shi JY; Li JY
    Leuk Res; 2009 Aug; 33(8):1141-3. PubMed ID: 19304323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
    Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
    Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.